Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial. J BASELGA et al
Concordance in Hormone Receptors and HER2 Expression between Primary Breast Cancer, Loco-Regional Recurrences and Distant Metastases. Subgroups Analysis and Predictors of Discordance. FE PETRACCI et al
TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI). Thomas BACHELOT et al
High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients. JY PIERGA et al.
Monitoring Circulating Tumor Cells (CTC) and circulating endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC) : An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial. J-Y PIERGA et al.
First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III , randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER 2- positive primary breast cancer. J BASELGA et al
Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). G VON MINCKWITZ et al
Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus Tamoxifen in the TEAM pathology sub-study . JMS BARTLETT et al
Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (‘NeoSphere’).
